(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 82.04% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Gossamer Bio's revenue in 2026 is $44,051,000.On average, 10 Wall Street analysts forecast GOSS's revenue for 2026 to be $7,598,477,133, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $21,702,495,000. On average, 10 Wall Street analysts forecast GOSS's revenue for 2027 to be $23,024,110,170, with the lowest GOSS revenue forecast at $4,491,177,017, and the highest GOSS revenue forecast at $53,103,006,749.
In 2028, GOSS is forecast to generate $67,272,758,191 in revenue, with the lowest revenue forecast at $40,287,274,353 and the highest revenue forecast at $86,087,836,509.